New Data Show In Vitro Potency of Doripenem Against Resistan...( WASHINGTON Oct. 27 /- Johnson & J...),Health

WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases (ESBLs) than other commonly used carbapenems.

Enterobacteriaceae is a large group of bacteria that can cause infections of the digestive tract or other organs of the body and includes common bacteria strains such as E. coli. These new data were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

In the study, the incidence and susceptibility of extended-spectrum Beta-lactamase producing Enterobacteriaceae (ESBLE) and ciprofloxacin-resistant Enterobacteriaceae (CIPRE) to doripenem and relevant comparators was evaluated. The data analyzed was pooled from six large, multi-national Phase III clinical trials, including trials that focused on complicated urinary tract infections (cUTIs) and pyelonephritis (2); complicated intra-abdominal infections (cIAI) (2); nosocomial pneumonia (NP), including early-onset ventilator-associated pneumonia (VAP) (1); and VAP, both early- and late-onset (1). The study results showed:

-- Against ESBLE and CIPRE, doripenem was generally more potent in vitro

than imipenem and ertapenem, and inhibited growth of CIPRE and ESBLE at

very low drug concentrations.

-- Doripenem, imipenem and ertapenem, inhibited growth of >90% of ESBLE

at concentrations of 0.25 micrograms/mL, 0.5 micrograms/mL, and 1

micrograms/mL, respectively.

-- Similarly, doripenem, imipenem and ertapenem inhibited the growth of

>90% of CIPRE at concentrations of 0.5 micrograms/mL, 1

m
'/>"/>